Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Stifel

Q3 Results Proved That the Stars Are Aligned for Micron Stock

Micron is enjoying a rally of almost 297% so far this year. Is it any wonder that Stifel reiterated its "Buy" rating on the stock?

Barchart

Blackberry Stock Just Scored a New 'Buy' Rating. Here's Why.

Blackberry stock rallies as Stifel announces a bullish $12 price target. Here’s why the investment firm recommends owning BB shares at current levels.

Barchart

US Stock Market: Barclays, Stifel lift S&P 500 year-end targets on stronger earnings outlook

Major financial firms Barclays and Stifel have boosted their S&P 500 year-end targets to 7,800, signaling strong confidence in corporate profits and the U.S. stock market's resilience. This optimism, fueled by AI advancements and improved investor sentiment, suggests further upside potential. While inflation and interest rate concerns linger, strategists see…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

These 2 Veteran Wall Street Firms Just Revamped Their Micron Stock Price Targets Ahead of Earnings

Analysts see more upside for Micron's business, though the stock now trades well above the Street's average price target.

Barchart

Why Citi Keeps Pounding the Table on Texas Instruments Stock

Citi sees Texas Instruments as a prime AI infrastructure beneficiary, raising its price target to $345 as the chipmaker positions itself to gain market share.

Barchart

Cadence Deal With Intel Backs Bullish Thesis on Cadence’s Agentic AI

Cadence's Agentic AI appears to be a positive game changer for its stock.

Barchart

This Analyst Just Upped the Price Target on Carnival Stock. Here’s Why.

Stifel raised its price target on Carnival stock to $36. Analyst Steven Wieczynski explained his bullish view on CCL shares in a research note today.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Analysts Turn Bearish on Adobe After Earnings. What’s Next for ADBE Stock.

Adobe stock sinks as CFO Dan Durn announces a sudden departure. Wall Street analysts are downgrading ADBE shares today.

Barchart

Why 102.4 Tbps AI-Optimized Switch Silicon Is Such a Huge Deal for Marvell Technology Stock

Marvell’s stock gained 32.5% after it introduced its Teralynx T100 switch silicon.

Barchart

IDEXX Laboratories Touts AI Push, inVue Dx Momentum at Stifel Conference

IDEXX Laboratories (NASDAQ:IDXX) President and CEO Michael Erickson used a Stifel investor conference appearance to emphasize the company’s innovation pipeline, expanding commercial reach and growing use of software and artificial intelligence across veterinary diagnostics. Erickson, who recently b

MarketBeat

Henry Schein Sees Steady Dental Demand, $125M Profit Lift by 2026

Henry Schein (NASDAQ:HSIC) executives said the company is on track with its 2026 commitments and value-creation plan, while pointing to continued momentum in the U.S. dental market despite broader concerns about consumer confidence. Speaking at a Stifel dental track event moderated by Stifel Managi

MarketBeat

Align Technology Highlights New Invisalign Solutions, Financing and Global Growth

Align Technology (NASDAQ:ALGN) executives highlighted product innovation, financing initiatives and international expansion as key growth drivers during a discussion at the 2026 Stifel Jaws & Paws Conference. Chief Financial Officer John Morici, joined by Shirley Stacy, vice president of financ

MarketBeat

Wall Street's 6 Top World Cup Stock Picks

The World Cup kicks off this month and could give the global economy a $40 billion jolt. These are some of the stocks analysts think could benefit.

Kiplinger

MacroGenics Eyes $200M Cash Boost, 2028 Runway Ahead of Cancer Pipeline Updates

MacroGenics (NASDAQ:MGNX) Chief Executive Officer Eric Risser said the biotechnology company has strengthened its balance sheet through two recent transactions while preparing for a series of clinical updates across its oncology pipeline. Speaking during an informal discussion hosted by Stifel seni

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Lyell Immunopharma Targets 2027 FDA Filing as CAR-T Pipeline Advances

Lyell Immunopharma (NASDAQ:LYEL) President and CEO Lynn Seely outlined the company’s clinical development priorities, regulatory strategy and manufacturing plans during a Stifel investor session moderated by Stephen Willey, senior biotech analyst at Stifel. Seely described Lyell as a cell therapy c

Barchart

The Trump-Intel Deal Stole Headlines, But the President Also Bought Nvidia Stock in Q1

President Trump bought up to $5 million shares in Nvidia, but a Chinese reopening seems like a faraway thought now.

Barchart

Why You Should Buy Marvell Technology Stock Before May 27

Despite triple-digit gains in 2026, Marvell continues to post strong revenue growth fueled by booming data center demand.

MarketBeat

IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing

IDEAYA Biosciences (NASDAQ:IDYA) Chief Executive Yujiro Hata said the precision oncology company is preparing for a busy 2026, led by regulatory and clinical milestones for darovasertib in metastatic uveal melanoma and multiple data readouts across its pipeline. Speaking at a Stifel-hosted event, H

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Stifel Just Raised Its Price Target on Palo Alto Networks. Here's Why.

Palo Alto Networks stock rallies on a bullish note from Stifel analysts. Here’s why the investment firm sees PANW shares pushing higher in 2026.

MarketBeat

Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer

Adagene (NASDAQ:ADAG) Chief Strategy Officer Mickael Chane-Du outlined the company’s clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst Stephen Willey, emphasizing the company’s focus on improving the therapeutic index of CTLA-4 inhibition

Barchart

Why This Analyst Thinks Texas Instruments Stock Is on the Path to $1 Trillion

While most are chasing flashy AI chipmakers, Stifel believes Texas Instruments could become the world’s first $1 trillion analog semiconductor stock.

Barchart

This Analyst Just Raised the Price Target on Coherent Stock by 50%. What to Know.

Coherent stock rallies as Stifel issues a bullish note. Here’s why analyst Ruben Roy sees COHR shares ripping higher from current levels as the year unfolds.

Fortune

Goldman: AI will save the economy someday. First, it has to stop inflating it

The AI productivity boom hasn't quite arrived yet, but the inflation from building it has. Maybe Gen Z is onto something with their AI rebellion.

Barchart

With a 76% Post-Earnings Rally, MaxLinear May Have Just Become the Top AI Infrastructure Stock to Buy

Maxlinear is well-positioned to continue benefiting from the ongoing growth of hyperscalers' data centers.

Barchart

AMD Stock Just Hit New All-Time Highs. Should You Buy Shares Here?

Despite its recent rally, AMD's valuation remains favorable.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.